-
Pfizer’s Remicade biosimilar displays similar efficacy
pharmafile
February 23, 2017
Pfizer and Celltrion have announced new data for their Remicade biosimilar, Inflectra, that shows that the drug is comparable in safety and efficacy, in a recent Phase 3 trial treating Crohn’s disease. Remicade was worth sales of $5.76 billion to Johnson
-
Pfizer announces closure of its Australian facility
biospectrumasia
February 20, 2017
Located in the South Australia city of Adelaide, the facility has a staff of 89
-
Pfizer CentreOne Expands Fill-Finish Services
contractpharma
February 17, 2017
Kalamazoo, MI, facility to provide vial-filling of small and large molecules plus sterile suspensions
-
Relationship expert teams up with Pfizer to address intimacy and relationship issues for people livi
worldpharmanews
February 13, 2017
Nationally-recognized relationship expert and author, Logan Levkoff, Ph.D., has partnered with Pfizer Inc. (NYSE:PFE) to fill a void in information available to people living with chronic diseases: relationship advice.
-
Pfizer registers net profit of Rs 60.5 crore in quarter ended December 2016
financialexpress
February 07, 2017
Pfizer posts a revenue of Rs 504 crore in the same period
-
Biosimilars market is expected to worth USD10.90 billion by 2021
pharmaasia
January 25, 2017
The major factors driving the growth of this market are the increasing demand, and government support and initiatives to develop and promote biosimilars.
-
Pfizer partners with Cambridge matchmaker Milner
pharmatimes
January 24, 2017
Pfizer is the latest pharma giant to join Cambridge-based Milner Therapeutics Consortium, a global therapeutic alliance that aims to enable the transfer of materials between industry and academia.
-
Milner Therapeutics Institute Announces Partnership with Pfizer
americanpharmaceuticalreview
January 20, 2017
The Milner Therapeutics Institute has announced that Pfizer has joined as a partner to the Milner Therapeutics Consortium.
-
Pfizer, AbCellera in Multi-Target Research Pact
contractpharma
January 06, 2017
Aims to generate lead antibody candidates using AbCellera’s mAb discovery platform.